tbuckley/cabot-search huggingface dataset:
European Antimicrobial Resistance Surveillance System (EARSS) : susceptibilité des Staphylococcus aureus invasifs
Authors: I Veldhuijzen, S L A M Bronzwaer, J Degener, J. L. Kool, Earss participants
Journal: Eurosurveillance (2000)

Plus de 400 laboratoires participent a EARSS (European Antimicrobial Resistance Surveillance System) et envoient leurs donnees a l’Institut National de Sante Publique et de l’Environnement (RIVM) aux Pays-Bas. Les donnees concernant pres de 14 000 isolats sanguins de Staphylococcus aureus et de pres de 6000 isolats de Streptococcus peumoniae y sont attendues chaque annee. Les donnees publiees a l’issue de la phase de faisabilite de 18 mois suggerent que la resistance a la meticilline parmi les isolats sanguins de S. aureus est plus frequente dans les pays du sud de l’Europe que dans les pays du nord.
Association of Health Literacy With Postoperative Outcomes in Patients Undergoing Major Abdominal Surgery
Authors: Jesse P. Wright, Gretchen C. Edwards, Kathryn Goggins, Vikram Tiwari, Amelia Maiga, Kelvin Moses, Sunil Kripalani, Kamran Idrees
Journal: JAMA Surgery (2017)

<h3>Importance</h3> Low health literacy is known to adversely affect health outcomes in patients with chronic medical conditions. To our knowledge, the association of health literacy with postoperative outcomes has not been studied in-depth in a surgical patient population. <h3>Objective</h3> To evaluate the association of health literacy with postoperative outcomes in patients undergoing major abdominal surgery. <h3>Design, Setting, and Participants</h3> From November 2010 to December 2013, 1239 patients who were undergoing elective gastric, colorectal, hepatic, and pancreatic resections for both benign and malignant disease at a single academic institution were retrospectively reviewed. Patient demographics, education, insurance status, procedure type, American Society of Anesthesiologists status, Charlson comorbidity index, and postoperative outcomes, including length of stay, emergency department visits, and hospital readmissions, were reviewed from electronic medical records. Health literacy levels were assessed using the Brief Health Literacy Screen, a validated tool that was administered by nursing staff members on hospital admission. Multivariate analysis was used to determine the association of health literacy levels on postoperative outcomes, controlling for patient demographics and clinical characteristics. <h3>Main Outcomes and Measures</h3> The association of health literacy with postoperative 30-day emergency department visits, 90-day hospital readmissions, and index hospitalization length of stay. <h3>Results</h3> Of the 1239 patients who participated in this study, 624 (50.4%) were women, 1083 (87.4%) where white, 96 (7.7%) were black, and 60 (4.8%) were of other race/ethnicity. The mean (SD) Brief Health Literacy Screen score was 12.9 (SD, 2.75; range, 3-15) and the median educational attainment was 13.0 years. Patients with lower health literacy levels had a longer length of stay in unadjusted (95% CI, 0.95-0.99;<i>P</i> = .004) and adjusted (95% CI, 0.03-0.26;<i>P</i> = .02) analyses. However, lower health literacy was not significantly associated with increased rates of 30-day emergency department visits or 90-day hospital readmissions. <h3>Conclusions and Relevance</h3> Lower health literacy levels are independently associated with longer index hospitalization lengths of stay for patients who are undergoing major abdominal surgery. The role of health literacy needs to be further evaluated within surgical practices to improve health care outcomes and use.
Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway
Authors: K Kondo, H Shaim, P A Thompson, J A Burger, M Keating, Z Estrov, D Harris, E Kim, A Ferrajoli, M Daher, R Basar, M Muftuoglu, N Imahashi, A Alsuliman, C Sobieski, E Gokdemir, W Wierda, N Jain, E Liu, E J Shpall, K Rezvani
Journal: Leukemia (2017)
Metabolomics in cancer cachexia
Authors: J.A. Lopez-Martin, M. Cala, E. Prieto-García, C. Gonzalez Riano, C.V. Díaz-García, A. García, V. Pardo Marqués, F. Ruperez Pascualena, I. García-Ruiz, C. Pernaut, I. Otero, L. Parrilla Rubio, M.C. Riesco, J. Adeva Alfonso, C. Barbas, M.T. Agulló-Ortuño
Journal: Annals of Oncology (2017)
Vigilancia de agentes patógenos respiratorios y síndromes gripales en consultas de medicina general – Países Bajos, invierno de 1997-98
Authors: M. L.A. Heijnen, J W Dorigo-Zetsma, A I M Bartelds, B Wilbrink, M. J.W Sprenger
Journal: Eurosurveillance (1999)

Desde 1970, el Instituto Holandes para la Atencion Sanitaria Primaria (NIVEL) de los Paises Bajos coordina las actividades de una red centinela de vigilancia en la que participan 43 consultas de medicina general. Estas consultas atienden al 1% de la poblacion holandesa, una muestra representativa de la poblacion nacional en cuanto a edad, sexo y grado de urbanizacion (1). NIVEL utiliza los datos de la red para calcular, cada semana durante la temporada invernal, la incidencia de sindromes gripales. A peticion de NIVEL, el sistema ha incluido mejoras, desde el invierno de 1992-93, gracias al Instituto Nacional de Sanidad y Medio Ambiente (Rijksinstituut voor Volksgezondheid en Milieu -RIVM-), y ahora incluye aislamiento y deteccion de virus a partir de muestras nasofaringeas obtenidas de pacientes con infecciones agudas del tracto respiratorio superior (IRA), de las cuales los sindromes gripales representan, como promedio, mas del 62%.
Effect of MEK inhibition on PD-L1 and MCH-1 expression and on cytokines production profile in NSCLC cells and in human lymphocites
Authors: C.M. Della Corte, G. Barra, V. Ciaramella, F. Papaccio, G. Viscardi, G. Esposito, R. Di Liello, M. Orditura, T. Troiani, R. De Palma, F. Ciardiello, F. Morgillo
Journal: Annals of Oncology (2017)
Current Shortcomings of Camera Screening
Authors: Rajeev S. Ramchandran, Steven E. Feldon, Cynthia Owsley
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Tumor microenvironment biomarkers as therapeutic strategies for TNBC
Authors: F. Rojo, M. Ruiz Borrego, M. Hui, J.M. Trigo Perez, A. Cazet, M.A. Karsdal, A. Urruticoechea, S. Antolin, J.A. García-Saenz, S. O’Toole, A. Blach, L. Perez-Ramos, S. Bezares, M. Sánchez-Aragó, R. Caballero, C.L. Bager, A. Swarbrick, M. Martin Jimenez
Journal: Annals of Oncology (2017)
Variations in PD1, PD-L1, IDO1 and VEGR2 genes and association with outcomes in advanced head and neck squamous cell carcinoma (HNSCC) patients treated with anti-PD1/PD-L1 based immunotherapy
Authors: E. Saâda-Bouzid, S. Refae, N. Ebran, J. Gal, F. Peyrade, J. Guigay, G. Milano
Journal: Annals of Oncology (2017)
Cytochrome Oxidase and &lt;italic&gt;d&lt;/italic&gt;-Amino Acid Oxidase in Tumor Tissue
Authors: Shack, Joseph
Journal: JNCI Journal of the National Cancer Institute (1943)

Journal Article Cytochrome Oxidase and d-Amino Acid Oxidase in Tumor Tissue Get access Joseph Shack Joseph Shack research fellow National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 3, Issue 4, February 1943, Pages 389–396, https://doi.org/10.1093/jnci/3.4.389 Published: 01 February 1943
The prognostic significance of distant metastasis free interval (DMFI) in BRAF mutant advanced melanoma patients treated with first line targeted therapy
Authors: D. Bafaloukos, H. Linardou, P. Diamantopoulos, T. Sergentanis, A. Laskarakis, K-M. Giati, A. Tarampikou, A. Anastasopoulou, H. Gogas
Journal: Annals of Oncology (2017)
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology–Friends of Cancer Research HIV Working Group
Authors: Thomas S. Uldrick, Gwynn Ison, Michelle A. Rudek, Ariela Noy, Karl Schwartz, Suanna Bruinooge, Caroline Schenkel, Barry Miller, Kieron Dunleavy, Judy Wang, Jerome Zeldis, Richard F. Little
Journal: Journal of Clinical Oncology (2017)

Purpose People with HIV are living longer as a result of effective antiretroviral therapy. Cancer has become a leading cause of morbidity and mortality in this patient population. However, studies of novel cancer therapeutics have historically excluded patients with HIV. Critical review of eligibility criteria related to HIV is required to accelerate development of and access to effective therapeutics for HIV-infected patients with cancer and make studies more generalizable to this patient population. Methods From January through April 2016, the HIV Working Group conducted a series of teleconferences; a review of 46 New Drug Applications from registration studies of unique agents studied in adults with cancer that led to the initial US Food and Drug Administration approval of that agent from 2011 to 2015; and a review of HIV-related eligibility criteria from National Cancer Institute-sponsored studies. Results were discussed and refined at a multistakeholder workshop held May 12, 2016. The HIV Working Group developed recommendations for eligibility criteria that focus on pharmacologic and immunologic considerations in this patient population and that balance patient safety, access to appropriate investigational agents, and study integrity. Results Exclusion of patients with HIV remains common in most studies of novel cancer agents. Models for HIV-related eligibility criteria in National Cancer Institute-sponsored studies are instructive. HIV infection itself should no longer be an exclusion criterion for most studies. Eligibility criteria related to HIV infection that address concurrent antiretroviral therapy and immune status should be designed in a manner that is appropriate for a given cancer. Conclusion Expanding clinical trial eligibility to be more inclusive of patients with HIV is justified in most cases and may accelerate the development of effective therapies in this area of unmet clinical need.
A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).
Authors: Lauren Christine Harshman, Maneka Puligandla, Naomi B. Haas, Mohamad Allaf, Charles G. Drake, David F. McDermott, Sabina Signoretti, David Cella, Rajan T Gupta, Rupal Satish Bhatt, Eliezer Mendel Van Allen, Toni K. Choueiri, Primo Lara, Anil Kapoor, Daniel Yick Chin Heng, Brian M. Shuch, Michael A.S. Jewett, Daniel J. George, M Dror Michaelson, Michael Anthony Carducci
Journal: Journal of Clinical Oncology (2017)

TPS4596 Background: The anti-PD-1 antibody nivolumab (nivo) improves overall survival (OS) in metastatic treatment refractory RCC and is generally tolerable. In 2017, there is no standard adjuvant therapy proven to increase OS over surgery alone in non-metastatic (M0) disease. Mouse solid tumor models have revealed an OS benefit with a short course of neoadjuvant PD-1 blockade compared to adjuvant therapy. Two ongoing phase 2 studies of perioperative nivo in RCC patients (pts) have shown preliminary feasibility and safety with no surgical delays or complications. The PROSPER RCC trial will examine if the addition of perioperative nivo to radical or partial nephrectomy can improve clinical outcomes in pts with locally advanced RCC. With the goal of increasing cure and recurrence-free survival (RFS) rates in M0 RCC, we propose a three-pronged, multidisciplinary approach of presurgical priming with nivo followed by resection and adjuvant PD-1 blockade. Methods: Tumorbiopsy prior to randomization is mandatory to ensure the correct diagnosis and will permit unparalleled correlative science in this global, randomized, unblinded, phase 3 National Clinical Trials Network study. 766 pts with clinical stage ≥T2 or any node positive M0 RCC of any histology will be enrolled. The study arm will receive nivo 240mg IV for 2 doses prior to surgery followed by nivo adjuvantly for 9 months (q2 wks x 3 mo followed by q4 wks x 6 mo). The control arm will undergo the current standard of care: surgical resection followed by observation. Pts are stratified by clinical T stage, node positivity, and histology. There is 84.2% power to detect a 14.4% absolute increase in the primary endpoint of RFS from the ASSURE historical control of 55.8% to 70.2% at 5 yrs (HR 0.70). The study is also powered to detect a significant OS benefit (HR 0.67). Key safety, feasibility, and quality of life endpoints are incorporated. PROSPER RCC exemplifies team science with a host of planned correlative work to investigate the significance of the baseline immune milieu and changes after neoadjuvant priming and to identify predictive gene expression patterns. Additional collaborations are welcomed.
VinoMetro: Phase II study of metronomic daily oral vinorelbine as first-line chemotherapy in advanced/metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer resistant to endocrine therapy
Authors: T. Elger, T. Decker, T. Fehm, S. Fuxius, N. Harbeck, I. Juhasz-Böss, V. Möbus, C. Thomssen, M. Seehase, L. Schollenberger, C. Ruckes, M. Schmidt
Journal: Annals of Oncology (2017)
Results of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)
Authors: A. Stenzl, S. Feyerabend, I. Syndikus, T. Sarosiek, H. Kübler, A. Heidenreich, R. Cathomas, C. Grüllich, Y. Loriot, S.L. Perez Gracia, S. Gillessen, U. Klinkhardt, A. Schröder, O. Schönborn-Kellenberger, V. Reus, S.D. Koch, H.S. Hong, T. Seibel, K. Fizazi, U. Gnad-Vogt
Journal: Annals of Oncology (2017)
Prophylactic Ureteral Stent Placement vs No Ureteral Stent Placement During Open Colectomy
Authors: Jonathan Merola, Brian Arnold, Valerie Luks, Christopher Ibarra, Benjamin Resio, Kimberly A. Davis, Kevin Y. Pei
Journal: JAMA Surgery (2017)

This cohort study compares the outcomes of open colectomy with ureteral stenting with the outcomes of open colectomy without ureteral stenting.
Development of a predictive microRNA signature for node-negative breast cancer
Authors: Wei Shi, Angela Hui, Paul C Boutros, Naomi Miller, Melania Pintilie, Derek Wong, Kate Gerster, Linda Z Penn, Igor Jurisica, David McCready, Tony Fyles, Fei-Fei Liu
Journal: Cancer Research (2008)

4427    Introduction:    Small  noncoding RNAs (miRNAs) negatively regulate target gene expression at both the transcriptional and translational levels. Accumulating evidence indicates that aberrant expression of miRNAs is involved in cancer development and progression. Hypothesizing that there is a miRNA signature specific to lymph node negative (LNN) invasive breast cancer (BC) that could be used to predict disease recurrence, we performed global miRNA expression profiling on surgically excised LNN breast tumors.      Experimental Procedures:  Seventy-four archival formalin fixed and paraffin embedded (FFPE) lumpectomy blocks were selected: 34 from patients with relapse and 40 from patients without relapse. After macro-dissection, total RNA was isolated, and the level of expression of 365 human and 3 reference miRNAs were measured using qRT-PCR (TaqMan Low Density Array platform (Applied Biosystem)). Six reductional mammoplasty were also analyzed as “normal” comparators. ER and Her2/neu expression were assessed by immunohistochemistry. Unsupervised pattern recognition was performed with agglomerative hierarchical clustering. Tumour-normal comparisons were done using the t-test with Welch’s correction for unequal variances.   Results:  Amongst these 74 patients, 62 (84%) were ER positive while 12 (16%) were ER negative. Her-2/neu assessments indicated that 60 patients (81%) were her-2/neu negative, while 6 (8%) were positive, and the remaining 8 (11%) were equivocal. We analyzed the technical reproducibility of representative normal and tumour samples, and found excellent inter-experimental reproducibility. Correlation coefficients exceeded 0.95. Amongst the 365 miRNAs assayed, 244 (67%) showed expression in breast epithelial tissues. Unsupervised pattern recognition showed that miRNA expression naturally separates tumour  vs . normal tissues into separate groups. In total, 68 miRNAs were significantly differentially expressed (p vs . non-relapsed samples, suggesting that there is a subset of miRNAs whose expression could be associated with a higher risk of BC recurrence. Data on miRNA expression patterns associated with ER or her2/neu expression will also be presented.   Conclusion:  Our data demonstrate for the first time, that global miRNA expression profiling can be conducted successfully from FFPE breast cancer specimens. Furthermore, we have identified a distinct subset of miRNAs whose expression pattern in LNN invasive BC could be associated with clinical outcome. These results suggest that a miRNA signature could be used as a predictive marker for human breast cancer.
Pansclerotic morphea associated with hypohidrosis and anti-M3 muscarinic acetylcholine receptor antibodies
Authors: H. Fujita-Tanaka, Y. Ogawa, Y. Muro, M. Ogawa-Momohara, H. Asashima, H. Tsuboi, T. Sumida, M. Akiyama
Journal: British Journal of Dermatology (2017)
Modeling of Tumor Kinetics and Overall Survival to Identify Predictive Factors for Efficacy of Durvalumab in Patients with Urothelial Carcinoma (UC)
Authors: Y. Zheng, X. Jin, R. Narwal, C-Y. D Jin, A. Gupta, Y. Ben, P. Mukhopadhyay, B. Higgs, L. Roskos
Journal: Annals of Oncology (2017)
Emisión intencionada de agentes biológicos: primeras lecciones para Europa tras los eventos ocurridos en los Estados Unidos
Authors: R Harling, B Twisselmann, N Asgari, D Morgan, N Lightfoot, M Reacher, A Nicoll
Journal: Eurosurveillance (2001)

Los acontecimientos ocurridos en otono de 2001, cuando se produjo el envio de cartas conteniendo esporas de B. anthracis, han tenido importantes consecuencias en los Estados Unidos y en Europa. La amenaza de atentados no reivindicados contra la poblacion civil se ha convertido en realidad. En Europa, a pesar del creciente numero de falsas alarmas, no se han declarado casos de carbunco vinculados a emisiones intencionadas y las unicas cartas contaminadas iban dirigidas a las Embajadas Norteamericanas. Pese a ello, es hora de que Europa establezca unos planes eficaces y puntuales para responder al bioterrorismo, bajo la coordinacion de la Comision Europea.
Programa de epidemiologia de campo aplicada em Espanha
Authors: J. F. Martinez Navarro, D Herrera, Candi Sanchez Barco
Journal: Eurosurveillance (2001)

Em 1994, o Instituto de Saude Carlos III (Instituto de Salud Carlos III; ISCIII) do Ministerio da Saude e do Consumidor de Espanha (MSC) criou o Programa de Epidemiologia de Campo Aplicada (PEAC; Applied Field Epidemiology Programme). A gestao do programa e efectuada pelo Centro Nacional de Epidemiologia (Centro Nacional de Epidemiologia) em colaboracao com a Escola Nacional de Saude (Escuela Nacional de Sanidad); o programa e financiado pela Direccao Geral de Saude e do Consumidor do MSC e pelos Concelhos de Saude (Consejerias de Sanidad) das regioes autonomas.
The Antigens of Human Leukocytes. I. Introduction&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Leonhard Korngold, Gerda van Leeuwen, Daniel G. Miller
Journal: JNCI Journal of the National Cancer Institute (1961)

Methods for the preparation of human leukocyte antigens for immunization and analysis by gel diffusion are presented. Contamination of these antigens by serum proteins was shown to be less than 2 percent. The properties of the antileukocyte serums are described.
Helicobacter pylori Employs a Unique Basolateral Type IV Secretion Mechanism for CagA Delivery
Authors: Nicole Tegtmeyer, Silja Wessler, Vittorio Necchi, Manfred Rohde, Aileen Harrer, Tilman T. Rau, Carmen Isabell Asche, Manja Boehm, Holger Loessner, Ceu Figueiredo, Michael Naumann, Ralf Palmisano, Enrico Solcia, Vittorio Ricci, Steffen Backert
Journal: Cell Host & Microbe (2017)
A global phase III clinical study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients
Authors: T. Saeki, H. Mukai, J. Ro, Y-C. Lin, Y. Fujiwara, S. Nagai, K.S. Lee, J. Watanabe, S. Ohtani, S.B. Kim, K. Kuroi, K. Tsugawa, Y. Tokuda, H. Iwata, Y.H. Park, Y. Yang, Y. Nambu
Journal: Annals of Oncology (2017)
YKL-39 induces monocytes migration and angiogenesis and inversely correlates with metastasis in patients with breast cancer
Authors: I. Mitrofanova, L. Tengfei, M. Zavyalova, N. Litviakov, M. Buldakov, N. Cherdyntseva, J. Kzhyshkowska
Journal: Annals of Oncology (2017)
Recursos de laboratorio en Europa para identificar los virus transmitidos por alimentos
Authors: B A Lopman, Y T H P van Duynhoven, F X Hanon, M Reacher, M Koopmans, D W Brown
Journal: Eurosurveillance (2002)

En este informe se describen los resultados de una encuesta sobre los recursos nacionales de los laboratorios de diagnostico y sobre las bases de datos de virus transmitidos por alimentos, en el marco del consorcio Virus transmitidos por alimentos en Europa. Todos los paises disponen de laboratorios equipados para analizar anticuerpos anti-VHA en suero humano. De los diez paises europeos encuestados, ocho mantienen una base de datos nacional de casos de VHA. En Finlandia, Italia, Espana, Francia y Dinamarca se analiza la presencia de VHA en los alimentos. Todos los paises encuestados disponen al menos de un laboratorio que analiza virus Norwalk-like (VNL) por reaccion en cadena de la retrotranscriptasa-polimerasa (reverse transcriptase-polymerase chain reaction), y microscopia electronica. Cinco paises mantienen una base de datos nacional de casos de VNL y nueve mantienen una base de datos nacional de brotes de VNL. Casi todos los paises participantes disponen de laboratorios que pueden analizar el VNL en alimentos y marisco.
Circulating ApoJ is closely associated with insulin resistance in human subjects
Authors: Ji A. Seo, Min-Cheol Kang, Theodore P. Ciaraldi, Sang Soo Kim, Kyong Soo Park, Charles Choe, Won Min Hwang, Dong Mee Lim, Olivia Farr, Christos Mantzoros, Robert R. Henry, Young-Bum Kim
Journal: Metabolism (2017)
GW28-e1194 The role of new-onset atrial fibrillation after myocardial infarction in increasing cardiovascular risk: a systematic review and meta-analysis
Authors: Jiachen Luo, Liming Dai, Jianming Li, Jinlong Zhao, Yong Li, Guli Maihe, Xiaoming Qin, Hongqiang Li, Baoxin Liu, Yidong Wei
Journal: Journal of the American College of Cardiology (2017)